Beneficial effects on macrovascular end points observed in response to sustained metformin therapy argue in favor of this approach, according to new research from The Netherlands. The results ...

Atherosclerotic lesions causing macrovascular (cardiovascular) complications are similar whether hyperglycemia occurs in type 1 diabetes (absolute insulin deficiency) or type 2 diabetes (relative ...

New techniques have enabled the vascularization of synthetic cardiac tissues with significantly improved parity to in vivo ...

OBJECTIVE To determine if macrovascular disease is more prevalent in systemic sclerosis (SSc) compared with unaffected subjects. METHODS 54 patients with SSc (both limited and diffuse disease) and 43 ...

bHuman Diabetes and Metabolism Research Centre, School of Clinical Medical Sciences, Floor 4 William Leech Building, Medical School, Newcastle upon Tyne NE2 4HH, UK Macrovascular disease, in both ...

OBJECTIVE Macrovascular disease in scleroderma has recently been described in two comparative studies. The aim of this study was to map its anatomical distribution. METHODS In a retrospective cohort ...

If hyperglycemia is not the major determinant of diabetic macrovascular disease, what about the constellation of risk factors associated with insulin resistance and the metabolic syndrome?

Ultrasound plays a pivotal role in the assessment of organ transplant patients. It enables physicians to safely and easily ...

Radiomic Features,Training Set,3D Graph,3D Images,3D Point,Ability Of The Model,Balanced Accuracy,Binary Classification Task,COVID-19,Chest Computed Tomography Images,Chest Computed Tomography ...

Egypt: Curative liver resection (LR) can be safely carried out in carefully selected elderly patients with hepatocellular ...

BMD was positively correlated with BMI and negatively correlated with age, but not correlated with diabetes-specific parameters (therapy, HbBA1c, micro- and macrovascular complications ...

28 Among patients with HCC involving macrovascular invasion, hepatectomy improved about 20% OS than TACE (1 year, 81% vs 68%; 3 years, 46% vs 22%; 5 years, 20% vs 5%). TACE or camrelizumab plus ...